AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome

Phase 1

Withdrawn

Conditions: Primary Sjögren's Syndrome

Interventions: Drug: VAY736 lower dose
Drug: VAY736 higher dose

First Posted Date: 2015-07-13

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02495129

First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement

Phase 1

Completed

Conditions: Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery

Interventions: Drug: LNA043
Drug: Placebo

First Posted Date: 2015-07-08

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT02491281

Locations: 🇺🇸
Novartis Investigative Site, Phoenix, Arizona, United States

Efficacy and Safety Study of QVA149 in COPD Patients

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QVA149
Drug: Umeclidinium/vilanterol
Drug: Placebo (umeclidinium/vilanterol)
Drug: Placebo (QVA149)

First Posted Date: 2015-07-01

Last Posted Date: 2017-12-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 357

Registration Number: NCT02487446

Locations: 🇺🇸
Novartis Investigative Site, Tacoma, Washington, United States

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QVA149
Drug: Umeclidinium/vilanterol
Drug: Placebo (QVA149)
Drug: Placebo (umeclidinium/vilanterol )

First Posted Date: 2015-07-01

Last Posted Date: 2018-04-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 355

Registration Number: NCT02487498

Locations: 🇺🇸
Novartis Investigative Site, Greenfield, Wisconsin, United States

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Phase 2

Completed

Conditions: External Genital Warts

Interventions: Drug: Investigational Treatment
Drug: Aldara

First Posted Date: 2015-06-26

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 88

Registration Number: NCT02482428

Locations: 🇺🇸
Novartis Investigative Site, Arlington Heights, Illinois, United States

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

Phase 2

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Other: Placebo
Biological: QGE031
Biological: Omalizumab

First Posted Date: 2015-06-22

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 382

Registration Number: NCT02477332

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain

Phase 3

Completed

Conditions: Post Operative Dental Pain

Interventions: Drug: Diclofenac potassium
Drug: Ibuprofen
Drug: Placebo to diclofenac potassium
Drug: Placebo to ibuprofen

First Posted Date: 2015-06-19

Last Posted Date: 2016-10-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 328

Registration Number: NCT02476422

Locations: 🇺🇸
Novartis Investigative Site, Austin, Texas, United States

Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

Phase 3

Completed

Conditions: Psoriasis

Interventions: Biological: Secukinumab
Drug: Fumaric acid

First Posted Date: 2015-06-17

Last Posted Date: 2017-10-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 202

Registration Number: NCT02474082

Locations: 🇩🇪
Novartis Investigative Site, Stade, Germany

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis

Phase 3

Completed

Conditions: Moderate to Severe Plaque-type Psoriasis

Interventions: Drug: Secukinumab

First Posted Date: 2015-06-17

Last Posted Date: 2019-07-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 772

Registration Number: NCT02474069

Locations: 🇩🇪
Novartis Investigative Site, Wuppertal, Germany

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: INC280

First Posted Date: 2015-06-17

Last Posted Date: 2020-12-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT02474537

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Clinical Pharmacology of Miami, LLC., Miami, Florida, United States
🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States

and more 2 locations

Home Terms & Conditions Privacy Policy